A novel inhibitor of poly (ADP-ribose) polymerase-1 (PARP1)

Cancer Science & Therapy

ISSN: 1948-5956

Open Access

A novel inhibitor of poly (ADP-ribose) polymerase-1 (PARP1)

9th Indo Global Summit on Cancer Therapy

November 02-04, 2015 Hyderabad, India

Sayantani Karmakar and Rita Ghosh

University of Kalyani, India

Scientific Tracks Abstracts: J Cancer Sci Ther

Abstract :

Acridines are important for their diverse biological activities. We present here the poly (ADP-ribose)-polymerase1 (PARP1) inhibitory activity of an aryl-acridine (ACPH). The nuclear enzyme PARP1 is involved in DNA repair and inhibition of its activity potentiates cell killing by different agents. Some PARP1 inhibitors are therefore used in conjunction with chemotherapeutic agents in cancer therapy to potentiate their action. Using bioinformatics docking tools the binding of ACPH to human PARP1 was investigated. ACPH could bind to PARP1 by interacting with the catalytic important amino acids at its NAD+ binding pocket. In silico mutants created for some of the catalytically important amino acid residues revealed that ACPH could only bind to and inhibit those enzymes with PARP1 activity. The findings indicated that ACPH can be a potent PARP1 inhibitor. Post treatment with ACPH could sensitize both exponential growing and quiescent A375cells to killing after exposure to DNA damaging agent, possibly by inhibiting DNA repair. The intracellular NAD+ content of A375 cells were also assayed biochemically. NAD+ is the precursor for PAR formation in cells after DNA damage; hence depletion of NAD+ is indicative of PARP activity in damaged cells. No depletion in NAD+ level was observed in DNA-damaged cells on post treatment with ACPH. These findings confirmed the PARP1 inhibitory activity of ACPH. The findings are important as it revealed for the first time PARP1 inhibitory activity in an acridine derivative. Considering the importance of PARP1 inhibitors in cancer therapeutics, the findings could be important for new drug development.

Biography :

Sayantani Karmakar has completed her MSc from Department of Microbiology, University of Kalyani, West Bengal, India and is currently pursuing her PhD degree from the same University from Department of Biochemistry and Biophysics under supervision of Prof. Rita Ghosh. She is receiving fellowship from UGC-BSR grant and has two publications in two reputed journals. She has also presented a part of her work in a national seminar and in an international seminar.


Google Scholar citation report
Citations: 3968

Cancer Science & Therapy received 3968 citations as per Google Scholar report

Cancer Science & Therapy peer review process verified at publons

Indexed In

arrow_upward arrow_upward